-
Posted by
Two Blokes Apr 27 -
Filed in
Stock
-
2 views
One-year clinical trial data for the next-generation, investigational, Sphere-360\u2122 single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9\u2122 catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting GALWAY, Ireland and SAN DIEGO , April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera\u2122 family of technologies, including the next-generation Sphere-360\u2122 single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9\u2122 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal.
